f baybayin

EU universal charger rules come into forcef baybayin 。

None

NoneUnique opportunity for fast-tracked social integration, if only...

Common Myths About Dental Implants Debunked By Highland Implant CenterNonePlayStation Black Friday Deals: Score Epic Discounts on Games, Consoles, and Accessories!

( MENAFN - GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. “Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2024 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market. Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report: Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years. Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others , are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years. In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP) , a biotechnology company dedicated to developing high-purity, pathogen-specific bacteriophage therapeutics for chronic pulmonary diseases and antibiotic-resistant bacterial infections, today announced promising topline results from its Phase 2 "Tailwind" trial. The trial evaluated AP-PA02, a novel inhaled multi-phage therapeutic for treating chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections in patients with non-cystic fibrosis bronchiectasis (NCFB). In May 2024, Insmed' s stock more than doubled following the announcement that its lead pipeline candidate, brensocatib, successfully completed a Phase III trial. The much-anticipated ASPEN trial (NCT04594369) was a global, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. In July 2023, Zambon, a global pharmaceutical company dedicated to innovating treatments and enhancing the health and well-being of patients, revealed the conclusive findings from the Phase 3 PROMIS-I and PROMIS-II studies. These results were unveiled during the 2023 6th World Bronchiectasis Conference held in New York, NY. Non-Cystic Fibrosis Bronchiectasis Overview Non-cystic fibrosis bronchiectasis is a chronic lung condition characterized by the permanent widening and damage of the airways in the lungs, which leads to persistent coughing, excessive mucus production, and frequent respiratory infections. Unlike cystic fibrosis, it is not caused by a genetic defect in the CFTR gene. Non-cystic fibrosis bronchiectasis can result from various underlying conditions such as chronic infections, immune system disorders, or other lung diseases. Symptoms include chronic cough, shortness of breath, and fatigue. Treatment typically involves antibiotics to manage infections, bronchodilators, and airway clearance techniques to reduce symptoms and improve lung function. Get a Free Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment- Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include: NP339: NovaBiotics Ltd Research Programme:NCFB: Synspira Therapeutics Research programme: mucolytic agents: Parion Sciences CHF 6333: Chiesi Farmaceutic CSL787: CSL Behring HSK31858: Haisco Pharmaceutical S-1226: SolAeroMed Inc. Benralizumab: AstraZeneca Colistimethate sodium: Zambon SpA BI 1291583: Boehringer Ingelheim AP-PA02: Armata Pharmaceuticals ARINA-1: Renovion Non-Cystic Fibrosis Bronchiectasis Route of Administration Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Intravenous Subcutaneous Oral Intramuscular Non-Cystic Fibrosis Bronchiectasis Molecule Type Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as Monoclonal antibody Small molecule Peptide Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type DelveInsight's Non-Cystic Fibrosis Bronchiectasis Report covers around 15+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include: Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are - Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others. Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis: The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment. Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market. Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth. Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight Coverage: Global Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials Table of Contents 1. Non-Cystic Fibrosis Bronchiectasis Report Introduction 2. Non-Cystic Fibrosis Bronchiectasis Executive Summary 3. Non-Cystic Fibrosis Bronchiectasis Overview 4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment 5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics 6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III) 7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II) 8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I) 9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products 10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment 11. Non-Cystic Fibrosis Bronchiectasis Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Non-Cystic Fibrosis Bronchiectasis Key Companies 14. Non-Cystic Fibrosis Bronchiectasis Key Products 15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs 16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers 17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion 18. Non-Cystic Fibrosis Bronchiectasis Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. MENAFN23122024003238003268ID1109025433 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.CINCINNATI (AP) — The Cincinnati Bengals took care of business and won three straight games for the first time this season. Cincinnati is playing its best football, but it might be too late to sneak into the playoffs, with five teams battling for the two remaining AFC postseason spots. At 7-8, the Bengals are on the bubble along with two other teams that have the same record, the Colts and Dolphins. To have a chance, the Bengals will need to beat the visiting Denver Broncos (9-6) on Saturday, then try to take down the Steelers (10-5) at Pittsburgh in the regular-season finale. They'll need some help from other teams, too. The rub for the Bengals is that they have yet to beat a team with a winning record this season. Now with some momentum for the first time, the Bengals will have to clear that hurdle. “It’s just what it’s supposed to feel like for us. This is our expectation," coach Zac Taylor said after on Sunday. “We just put ourselves in a position to now play some real meaningful games. ... We found a way to get the win and now we can turn our focus to a short week and the Denver Broncos.” Joe Burrow became the first player in NFL history to throw for at least 250 yards and three or more touchdowns in seven consecutive games. One of his TD passes, to Tee Higgins, came as he was falling down. He finished 23 for 30 for 252 yards. ... Ja'Marr Chase continues to build his resume as he strives to win the receiving “triple crown.” He had six catches for 97 yards and a touchdown against the Browns and leads the league in receptions, yards and TDs. ... K Cade York tied a franchise record with a 59-yard field goal. “The guys have responded this way all season,” Taylor said. “We lost some heartbreakers to be quite frank, and games that just came down to the end. It doesn’t mean that we’ve had a bad football team and we weren’t in it. We’ve been in this, and now — I don’t want to say getting our confidence back, because we’ve had confidence — but we’re just making the plays necessary at the critical points of the game to take control of these games. That’s really what’s happened the last three weeks, and we’ve got to continue that.” Burrow has fumbled 10 times this season. Against the Browns, he lost a fumble on a strip-sack with the Bengals on the Cleveland 2-yard-line. Last week, S Jordan Battle scooped a fumble and ran it all the way back, only to fumble as he crossed the goal line, leading to a touchback. Against the Browns, he intercepted a second-half pass from Dorian Thompson-Robinson in the end zone. The Bengals' defense has nine takeaways in the past two games. Cincinnati's depleted offensive line allowed four sacks. The offensive line took a hit when tackle Amarius Mims went out with an ankle injury and didn't return. 5.1 — Yards per carry by RB Chase Brown, who seems to get better every week. He had 18 carries for 91 yards. The Bengals continue their improbable effort to slip into the playoffs when they host the Broncos in their home finale on Saturday. They finish the season the following week at Pittsburgh. AP NFL:

How ‘The Boys’ Shaped the Emotional Journey of Season 4

Emma Roberts' 4-year-old son is her ‘double' in adorable birthday postCINCINNATI (AP) — The Cincinnati Bengals took care of business and won three straight games for the first time this season. Cincinnati is playing its best football, but it might be too late to sneak into the playoffs, with five teams battling for the two remaining AFC postseason spots. At 7-8, the Bengals are on the bubble along with two other teams that have the same record, the Colts and Dolphins. To have a chance, the Bengals will need to beat the visiting Denver Broncos (9-6) on Saturday, then try to take down the Steelers (10-5) at Pittsburgh in the regular-season finale. They'll need some help from other teams, too. The rub for the Bengals is that they have yet to beat a team with a winning record this season. Now with some momentum for the first time, the Bengals will have to clear that hurdle. “It’s just what it’s supposed to feel like for us. This is our expectation," coach Zac Taylor said after the Bengals beat the Cleveland Browns 24-6 on Sunday. “We just put ourselves in a position to now play some real meaningful games. ... We found a way to get the win and now we can turn our focus to a short week and the Denver Broncos.” Joe Burrow became the first player in NFL history to throw for at least 250 yards and three or more touchdowns in seven consecutive games. One of his TD passes, to Tee Higgins, came as he was falling down. He finished 23 for 30 for 252 yards. ... Ja'Marr Chase continues to build his resume as he strives to win the receiving “triple crown.” He had six catches for 97 yards and a touchdown against the Browns and leads the league in receptions, yards and TDs. ... K Cade York tied a franchise record with a 59-yard field goal. “The guys have responded this way all season,” Taylor said. “We lost some heartbreakers to be quite frank, and games that just came down to the end. It doesn’t mean that we’ve had a bad football team and we weren’t in it. We’ve been in this, and now — I don’t want to say getting our confidence back, because we’ve had confidence — but we’re just making the plays necessary at the critical points of the game to take control of these games. That’s really what’s happened the last three weeks, and we’ve got to continue that.” Burrow has fumbled 10 times this season. Against the Browns, he lost a fumble on a strip-sack with the Bengals on the Cleveland 2-yard-line. Last week, S Jordan Battle scooped a fumble and ran it all the way back, only to fumble as he crossed the goal line, leading to a touchback. Against the Browns, he intercepted a second-half pass from Dorian Thompson-Robinson in the end zone. The Bengals' defense has nine takeaways in the past two games. Cincinnati's depleted offensive line allowed four sacks. The offensive line took a hit when tackle Amarius Mims went out with an ankle injury and didn't return. 5.1 — Yards per carry by RB Chase Brown, who seems to get better every week. He had 18 carries for 91 yards. The Bengals continue their improbable effort to slip into the playoffs when they host the Broncos in their home finale on Saturday. They finish the season the following week at Pittsburgh. AP NFL: https://apnews.com/hub/NFL

Dharmendra Pradhan Graces 12th & 13th Combined Convocation of IIT Bhubaneswar

CHICAGO (WLS) -- The long lines at polling places in the weeks leading up to the election suggested high voter turnout, and Chicago election officials early on said they expected near record numbers. But that wasn't the case. The Chicago Board of Elections reported that only about 67.9% of registered voters turned out in this election. The only presidential election that was worse was in 1996. The highest turnout among age groups was those 25-to-34. "We matched some of the trends that happen nationally and across the state of Illinois, far less voters showing up on Election Day," Max Bever with the Chicago Board of Elections said. "When the dust settled, it looks like we have only around 45% of voters who showed up." Another possible factor was Kamala Harris' early support may have plateaued too soon. "I think it's because we are such a deeply blue state that there was a presumption that, you know, the Democratic candidate was going to win hands down," ABC7 Political Analyst Laura Washington said. "There was a lot of optimism about Kamala Harris, and maybe that led people to believe they didn't have to show up at the polls." A bright spot in this election was in the 44th Ward where the Chicago Board of Elections said more than 96% of registered voters cast their ballot. That high level of interest is something that was readily evident to Ellen Rosenfeld who capitalized on it to win a seat in the 4th district school board race. "I had voters say to me, 'I came out just to vote for the elected school board.' So, I believe it drove quite a bit of the voters out to make their voices heard, because they care about CPS, they care about the kids, and they care about what happens to our city," Rosenfeld said. "Out of everyone would cast their ballots. Nearly 80% of people voted within those school board races. That is a very high percentage, wise, when you look at school board races across the country," Bever added. That data reaffirming the old mantra that "all politics is local."A masked gunman fatally shot Brian Thompson , the CEO of UnitedHealthcare — one of the nation’s largest health insurers — outside a Manhattan hotel where the company was holding its investor conference on Wednesday, Dec. 4. Police are still searching for the gunman. A day after the shooting, a TikTok went viral claiming UnitedHealthcare posted a LinkedIn job listing for a new CEO within 24 hours of Thompson’s death. The job listing that appears in the video advertises a full-time, remote position based in Minnetonka, Minnesota, with an annual salary range of $300,000 to $450,000. Another viral TikTok claimed the company also posted the same job listing on Indeed. Many commenters on the viral TikToks questioned whether UnitedHealthcare actually posted a job listing for a new CEO directly following the fatal shooting. THE QUESTION Did UnitedHealthcare post a job listing for a new CEO the day after Brian Thompson’s death? THE SOURCES UnitedHealthcare UnitedHealth Group’s 2024 proxy statement Independent VERIFY searches of job openings on UnitedHealthcare’s LinkedIn , Indeed and official careers website Peter Deragon , a managing director at Stanton Chase in Los Angeles Liz Ryan , the CEO and founder of Human Workplace, a career coaching and consulting firm THE ANSWER No, UnitedHealthcare did not post a job listing for a new CEO the day after Brian Thompson’s death. Sign up for the VERIFY Fast Facts newsletter here . WHAT WE FOUND UnitedHealthcare did not post a job listing for a new CEO shortly the day after Brian Thompson was fatally shot in New York on Dec. 4, like two viral TikToks claimed. UnitedHealthcare is the largest subsidiary of the Minnetonka, Minnesota-based UnitedHealth Group. Thompson worked at UnitedHealth Group for 20 years. In April 2021, he was named UnitedHealthcare’s CEO after running the company’s Medicare and retirement business. On Dec. 6, VERIFY searched the most recent job listings posted on UnitedHealthcare’s LinkedIn and Indeed profiles and found that the company had not posted an ad for a new CEO within hours of Thompson’s death. We also found that the job was not listed on UnitedHealth Group’s official careers website . The salary range that appears in the viral TikTok’s fake job listing is also significantly lower than Thompson’s actual salary. In 2023, Thompson’s annual pay package, including salary, bonus and stock options awards, was $10.2 million, making him one of the company’s highest-paid executives, according to UnitedHealth Group’s 2024 proxy statement . Peter Deragon, a managing director at Stanton Chase, a global executive search and leadership consulting firm, says most companies don’t hire their CEOs through LinkedIn, Indeed or other online job boards. “Most C-suite executives don’t ‘hunt’ for a job in the traditional sense of the word. They aren’t found scouring job boards or parsing over the latest employment listings,” Deragon wrote in a blog post from January 2023. “Instead, C-suite professionals willing to shift between employers enter a different process. They position themselves favorably and are ‘courted’ by companies in need of quality leadership,” he added. Liz Ryan, the CEO and founder of Human Workplace, a career coaching and consulting firm, agrees. “Higher-level executives don’t get new jobs by filling out online applications and uploading their resumes,” Ryan wrote in November 2023. “They don’t job hunt that way because they’d never get hired if they did.” VERIFY reached out to UnitedHealthcare for comment but did not hear back by the time of publication. The Associated Press contributed to this report .Dutton promises teen ban won’t mean people need passports to log on

John Fesko Sells 669 Shares of Natera, Inc. (NASDAQ:NTRA) StockWASHINGTON , Nov. 22, 2024 /PRNewswire/ -- Bridge Defense, a defense-technology company, has made a strategic investment in Federated IT, a trusted provider of mission-critical services to the U.S. government. Founded in 2002, Federated IT has built a reputation as a trusted partner to the U.S. Intelligence Community and the Department of Defense. With expertise optimizing cloud computing, data center operations and migration, enterprise architecture, scientific research and analyses, and cybersecurity solutions, Federated IT consistently delivers technically excellent, secure, and reliable solutions that empower national security clients to achieve their objectives. "This investment represents a pivotal step in Bridge Defense's mission to create the next-generation systems integrator," said Jack Kilcoyne , co-founder of Bridge Defense. "We will combine the critical services Federated IT provides with in-house software development capabilities to build a hybrid organization capable of delivering exceptional services and developing innovative solutions that address our customers' most pressing challenges." Kyle von Bucholz , CEO of Federated IT, added: "For over 20 years, Federated IT has focused on solving our clients' most complex challenges with integrity and technical excellence. Partnering with Bridge Defense will enable us to take that commitment to the next level by leveraging cutting-edge development capabilities and delivering an even greater impact for the federal agencies we serve." About Bridge Defense Bridge Defense is focused on delivering mission-critical services and innovative software solutions to national security customers. A hybrid systems integrator, Bridge Defense combines excellence in technical services with native development capabilities to deliver comprehensive and transformative solutions to address the rapidly evolving needs of national security customers. Bridge Defense is led by a team of Special Operations veterans with deep expertise in technology and government services. The company is headquartered in the Northeast, with a growing presence in Washington, D.C. For more information, visit Bridge-Defense.com . About Federated IT Federated IT is a leading provider of mission-critical IT and cybersecurity services to the U.S. government. Federated IT enables defense, national security, and federal law enforcement clients to expand, improve, and strengthen critical IT infrastructure and mission system capabilities within the Tier Ill - IV Enterprise IT Operations and Cyber Security domains. Federated IT's project portfolio includes the customization and delivery of optimized cloud computing, data center operations and migration, enterprise architecture, scientific research and analyses, and cybersecurity solutions. Federated IT is headquartered in Washington, D.C. For more information, visit FederatedIT.com . View original content: https://www.prnewswire.com/news-releases/bridge-defense-announces-strategic-investment-in-federated-it-302314581.html SOURCE Bridge Defense

ISTANBUL Upholding Syria’s territorial integrity, political unity, and unitary structure are top priorities for Türkiye, the head of the country's Communications Directorate said in remarks published Monday. “Türkiye's priority is protecting Syria's territorial integrity, political unity, and unitary structure. This structure is essential to ensuring the integrity of the region and the future of the Syrian people,” Fahrettin Altun said in an interview with regional broadcaster Euronews. Highlighting Ankara's support for the legitimate demands and rights of Syrians, as well as its respect for their will, Altun said their resilience and endeavor to shape their future has been key. Altun said Ankara remains committed to this position in the aftermath of the Bashar Assad regime's downfall earlier this month, as well as to genuinely helping heal the wounds of the Syrian people, supporting their development, and promoting peace. "For this reason, we prioritize the peace and safety of the local population. To this end, we are working to ensure the voluntary, safe, and dignified return of Syrian refugees," he added. Guided by President Recep Tayyip Erdogan's vision, the Foreign Ministry is actively engaged in intensive diplomatic efforts and maintaining open communication channels with all regional parties to safeguard Syria's territorial integrity and achieve lasting peace, he added. Türkiye will not accept any attempts at political manipulation or ethnic division within Syrian territory under any circumstances, Altun vowed. He also warned that the presence of terrorist organizations in Syria poses a threat not only to the country’s border security but also the stability of the entire region. Reaffirming Türkiye’s stance against terrorism, Altun said Ankara pursues a solution-orientated policy based on justice and equity in cooperation with international actors, "whether it be the US, Russia, or Iran." “Türkiye, as the advocate of justice and protector of the oppressed, will persist in its endeavors for the peace and stability of the region,” he added. Türkiye never gives up its EU bid Pointing out Türkiye's longstanding effort to join the EU, Fidan said the country never gave up on its membership aspirations. Stating that Türkiye’s drive to join the bloc is an “intregral part of our strategic vision,” Altun said this is “more than just a foreign policy decision; it demonstrates our dedication to democracy, as well as our efforts for development and global collaboration.” He added that next year "may present new opportunities in this area. However, it is important to note that the European Union's approach is also a decisive factor in this process." Altun urged the EU to accept Türkiye as a member for the bloc to assume “an effective position on the global stage.” “Türkiye has always maintained an attitude of readiness to strengthen cooperation with the EU. We fundamentally anticipate the elimination of double standards in the accession process as well as the establishment of a constructive dialogue,” he said. Ankara is convinced that in the near future, there will be a strong need for the EU to strengthen its cooperation with it, especially to find joint solutions to both global and regional challenges, Altun said.The AP Top 25 men’s college basketball poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . EASTON, Pa. (AP) — Alex Chaikin led Lafayette over NCAA DivisionIII-member Rosemont on Sunday with 21 points off of the bench in a 91-45 victory. Chaikin went 7 of 11 from the field (5 for 9 from 3-point range) for the Leopards (2-4). T.J. Berger went 4 of 10 from the field (2 for 6 from 3-point range) to add 10 points. Andrew Phillips finished 4 of 6 from the field to finish with 10 points. Bruce Black led the Ravens in scoring, finishing with 11 points. Denelle Holly added eight points for Rosemont. Kelton Warren also recorded seven points. Lafayette took the lead with 20:00 left in the first half and did not give it up. Mike Bednostin led their team in scoring with eight points in the first half to help put them up 38-22 at the break. Lafayette outscored Rosemont by 30 points in the second half, and Chaikin scored a team-high 15 points in the second half to help their team secure the victory. NEXT UP Lafayette hosts LIU in its next matchup on Friday. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Longview vs. DeSoto

Fresh off a fellowship in cardiovascular disease at Hahnemann University Hospital, a young cardiologist arrived in Pottsville at the Reading Railroad Station on East Norwegian Street in 1972. Dr. Muhammad M. Munir came to join Dr. Benjamin Platt, whom he met at Hahnemann, in Dr. Norman Wall’s practice in Pottsville. It was his first practice, in a place he’d hardly ever heard of, and he stayed for 52 years until retiring from the staff of Lehigh Valley Health Network in July. Munir is notable for his dedication, vision and contribution to the health care of Schuylkill County. “My patients were like family to me,” the 83-year-old retired physician said in a recent interview. “They were responsible for me staying here as long as I have.” In retirement, he maintains contact with some of his patients, making sure they are well taken care of. He continues to read medical journals, keeping abreast of the latest developments in cardiology. Dr. Munir was honored recently during a gala at Arrow Studio & Events in Pottsville, organized by his daughter, Farrah, a pediatric cardiologist at Mount Sinai Hospital in New York. Among the 135 guests was Dr. Abdul Wahhab, a colleague who practiced surgery in Pottsville for 42 years before retiring in 2015. A skilled artist whose work hangs in Lehigh Valley Hospital-Schuylkill, Wahhab presented Munir with a commemorative painting. In 1977, Munir converted a former A&P supermarket into a Medical Arts Building on Claude A. Lord Boulevard in Pottsville. Joining him as partners were doctors Platt, Wahhab, Abdul Rashid and Ghaffar A. Zafar. During his career, Munir was directly or indirectly responsible for recruiting 15 young doctors of various specialties to practice in Schuylkill County. The son of a postmaster, he grew up in Rawalpindi, Pakistan, at a time of political turmoil. One of seven children, he says his mother’s commitment to education is largely responsible for him becoming a doctor. After graduating from Nishtar Medical College in Multan, Pakistan, in 1964, he did residencies in Albany, the Bronx, London and Maimonides Medical Center in Brooklyn before securing a two-year fellowship at Hahnemann. Seeing himself as an old-style clinician, Munir spent much of his time in face-to-face encounters with patients. Rarely did he use a computer during a consultation. “Medicine is not strictly a science,” he contends, “there is an art to it.” In addition to his spouse, Misbah, Munir was joined by his children, Shawn, Farrah and Omar at the gala. He was particularly happy that so many of the nurses he worked with at the former Good Samaritan Hospital were able to attend the gala. Nurses, perhaps more than anyone in the medical profession, helped him throughout his career, he says. Long a resident of Howard Avenue in Pottsville, Munir currently lives in Cressona.

Vance takes on a more visible transition role, working to boost Trump’s most contentious picksWhen three children must choose between bullying a fellow classmate or getting bullied themselves, will they give in to fear or do the right thing? That question, simple yet relatable for many children, is the subject of a colorful new children’s book written by Joe Kulbacki called “The Think It Through Crew.” “It has some of the steps a kid can take when they’re being bullied or see someone getting bullied, like getting help or telling a teacher,” said Kulbacki, director of instructional technology at the Hermitage School District. The book tells the story of three fourth-grade friends named Max, Stan and Amanda, who are threatened by a fifth-grade bully to help him bully a classmate. To guide the three friends in the right direction, the Conscience Canary arrives and shows the students what could happen if they either give in to the bully’s demands or stand up to the bully. After the crew has a chance to think it through, they’re able to make the right decision — giving children some ideas to deal with real-life cases of bullying. Helping to tell the story are a series of bright, colorful and stylized illustrations by Hermitage graduate and artist Max Schaller, under the pseudonym “M. McGinnis.” “He does illustrations of a lot of different things, and he did a great job with this,” Kulbacki said of Schaller. The idea for the book first came about 10 or 15 years ago, when Kulbacki was teaching fourth and fifth grade in Lebanon, Pa. With plenty of students under his supervision and three daughters of his own, Kulbacki was used to reading plenty of children’s books. Story continues below video However, he was also familiar with many of the hardships and social situations that young children can find themselves in. This inspired him to write a book that would appeal to children while giving easy-to-follow instructions. “I’d been around kids enough that I knew what I wanted to teach them, I just had to figure out writing a book,” Kulbacki said. Work on the story itself started around seven years ago, and friends and family members involved in education helped develop and edit the story. Kulbacki discovered Schaller and asked him to illustrate the story, and the book was ultimately published through Amazon in early 2023. About 500 books have been sold so far, with many of those purchased by the United Way of Mercer County for the students involved in their summer program, Kulbacki said. Although he’s still learning the process behind advertising and promoting his work online, Kulbacki has had opportunities to share his work at local events such as the Hermitage Night Market. He’s also spoken at schools and libraries about the book and the importance of preventing bullying, and he has plans to write future books about similar topics for children, such as online safety. “The first book was about what to do when you see bullying, but there are so many things that children need to be aware of,” Kulbacki said. More information can be found on Amazon and at “The Think It Through Crew” on Facebook.

More Record Highs for TSXFrom Fossil Fuels to Renewables - How Offshore Incorporation is Powering the Green Transition

President-elect Trump wants to again rename North America's tallest peak